

Data Sharing Statement

Llombart-Cussac. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer. *JAMA Oncol.* Published October 07, 2021. doi:10.1001/jamaoncol.2021.4301

Data

Data available: No

Additional Information

Explanation for why data not available: Data collected within the PARSIFAL study will be made available to researchers whose full proposal for their use of the data has been approved by the PARSIFAL Trial Management Group, that includes a qualified statistician. The data required for the approved, specified purposes, and the trial protocol will be provided, after completion of a data sharing agreement, that will be set up by the study sponsor. The data will be made available 2 years after publication. Please address requests for data to the corresponding authors.